紫杉醇治疗中国人群非小细胞肺癌的系统评价

Paclitaxel in treating non-small cell lung cancer:A systematic review

目的:系统评价紫杉醇在非小细胞肺癌治疗中的临床疗效和安全性。方法:检索万方数据库。纳入含紫杉醇治疗非小细胞肺癌的随机对照研究。结果:共纳入25个随机对照研究,2160例非小细胞肺癌患者。Meta分析结果表明,含紫杉醇治疗方案的治疗反应率较对照组高[OR=1.12,95%CI(1.03,1.23)];致Ⅲ度及以上白细胞减少高于对照组[OR=1.35,95%CI(1.05,1.74)];致Ⅲ度及以上血小板减少低于对照组[OR=0.37,95%CI(0.24,0.58)];致Ⅲ度及以上消化道反应与对照组相近似[OR=1.24,95%CI(0.85,1.80)];治疗组与对照组化疗后的1年生存人数差异无明显区别[OR=1.15,95%CI(0.94,1.40)]。结论:紫杉醇治疗非小细胞肺癌有一定的疗效。由于本系统评价纳入的研究存在偏倚的可能,对结果的论证强度会有影响,期待有更多高质量的随机双盲对照试验加以证明。

AIM： To assess the clinical efficacy and safety of paclitaxel in treating non-small cell lung cancer. METHODS：The Wanfang database was searched. The randomized control studies on paclitaxel treating non-small cell lung cancer were brought into the research. RESULTS： A total of 25 randomized control studies with 2160 cases of small cell lung cancer were brought into the research. The Meta analysis showed that the response rate of taxol treatment prescription was higher than that of control group[OR= 1.12,95%CI（1.03,1.23）];The incidence rate of leukopenia at grade m and above was higher [OR = 1.35,95% CI （1.05, 1.74）] than that of control group;The incidence rate of induced thrombocytopenia at degree m and above was decreased compared with control group [OR：0.37,95%CI（0.24,0.58）];The incidence rate of induced digestive tract reactions at degre; There were no significant differences of 1-year survival between treatment group and control group after chemotherapy[OR= 1.15, 95%CI （0.94,1.40）]. CONCLUSION： There is a certain therapeutic effect of paclitaxel in treating non-small cell lung cancer. Since there is a possible existence of bias in this systematic review of research, the results will affect the strength of the argument and more high-quality randomized double-blind control trials were look forward.